A large scientific review which revealed that aspirin protected people aged 50-65 against gastrointestinal cancer, was unable to determine cancer benefits for those aged over 70. International researchers, who analysed around 200 papers, explained there was ‘uncertainty’ about the balance of benefits versus the risk of daily low-dose aspirin in older people. “For example the…Details
In terms of numbers, the biggest single study update so far this year belongs to Geelong, with more than 300 ASPREE participants and guests attending the event at Simonds Stadium (Kardinia Park) this month. A fantastic morning enjoyed by all.
Such was the huge response from ASPREE participants that the ACT ASPREE team held an additional study update in the afternoon to accommodate all the guests.
Pictured: ASPREE Chief Investigator in the ACT, Prof Walter Abhayaratna introduces himself to local participants and their guests.
Another fantastic audience! Around 180 ASPREE participants and guests living in and around north west Melbourne this week attended a study update at RMIT, Bundoora. The ASPREE team would like to thank RMIT for generously providing such a great venue for the day.
Terrific to meet 190 ASPREE participants and guests from Central Victoria in Bendigo today. Special thanks goes to ASPREE participants and long-time friends, Mr John Cross and Mrs Lois Coggin, who not only brought their partners to the update, but also very kindly featured in the local Bendigo newspaper, ‘The Addy’.
The Principal Investigator for the Australian arm of the ASPREE study, Professor John McNeil (pictured left), urges that reports on the benefits or the risks of daily aspirin in healthy people should be taken in context. “Most major health organisations will not ‘jump the gun’ and recommend aspirin to healthy people without evidence. They are not making…Details
Government and health authorities make recommendations based on scientific evidence that proves the benefit of a particular therapy outweighs the risks. All medications have side effects and low-dose aspirin is no exception. Aspirin is often prescribed for secondary prevention in people who have had a heart attack or stroke because research demonstrates that in this…Details
We’ve reached a number of very important milestones! Thank you to the ASPREE research team, GP co-investigators and most importantly the generosity of our wonderful participants in the study. ASPREE participants in the US and Australia = 16,500 ASPREE participants in Australia = 14,500 ASPREE participants in Victoria = 10,500 ASPREE participants in Tasmania= 2,000…Details
The US Food and Drug Administration’s (FDA) decision not to recommend aspirin for primary prevention due to a lack of scientific evidence, adds further support for the ASPREE study. In a statement issued on their website, the FDA reported that the potential benefits of aspirin had not yet been established against known risks, such as…Details
ASPREE jumped on board Yarra Trams’ Good Friday Appeal, resulting in two tram faces sporting the ASPREE logo.
The Good Friday Appeal is a major Easter fundraiser for Victoria’s Royal Children’s Hospital. The Yarra Trams initiative reportedly raised more than $30,000.